慢性淋巴细胞白血病患者接种SARS-CoV-2疫苗后T细胞记忆应答受损
本研究采用活化诱导标志物(AIM)试验评估慢性淋巴细胞白血病(CLL)患者接种COVID-19疫苗后的T细胞应答,发现28.60%的CLL患者无CD4+ T细胞记忆应答,61.90%的CLL患者CD8+ T细胞记忆应答受损,且CD4+ AIM+记忆应答受损与更严重的COVID-19感染相关。伊布替尼治疗对CD8+细胞IL-2产生有负面影响,而治疗持续时间对记忆应答有正面影响。作者认为AIM试验有望用于筛查和分类患者。
要点
- 28.60%的CLL患者对COVID-19疫苗无CD4+ T细胞记忆应答,健康对照全部有应答。
- 61.90%的CLL患者CD8+ T细胞记忆应答受损,健康对照为33.33%。
- CD4+ AIM+记忆应答受损与更严重的COVID-19感染相关。
核心结论
- 多数CLL患者对疫苗接种应答不佳,作者认为AIM试验有望用于筛查和分类患者。
研究设计与样本
- 研究采用活化诱导标志物(AIM)试验评估CLL患者与健康对照(HC)接种COVID-19疫苗后的spike特异性CD4+和CD8+ T细胞应答。
主要发现
- 所有健康对照均产生CD4+ T细胞记忆应答,而28.60%的CLL患者无应答。
- CD8+ T细胞记忆应答在61.90%的CLL患者和33.33%的健康对照中受损。
- CLL应答者CD8亚群记忆应答的幅度显著受损。
- CD4+ AIM+记忆应答受损与更严重的COVID-19感染相关。
- 伊布替尼治疗对CD8+细胞的IL-2产生有负面影响,而治疗持续时间对记忆应答有正面影响。
临床怎么用
- 作者认为AIM试验有望作为筛查和分类CLL患者的方法,以识别无应答者并评估有应答者的保护水平。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CLL patients face increased vulnerability to COVID-19 because of weakened immune systems from comorbidities and treatments. Therefore, the need for these patients of vaccination is of outermost importance. In our study we have evaluated T cell-mediated responses to COVID19 vaccines by performing the activation-induced markers (AIM) assay which allows to determine spike-specific CD4+ and CD8+ T cell responses. A CD4+ T cell memory response was registered in all healthy control (HC) (responders), while 28.60 % of CLL patients did not respond to the stimulation (non-responders). CD8+ T cell memory response was impaired in 61.90 % of CLL patients and in 33.33 % of HC. In addition, CLL responders showed a significant impairment of the magnitude of memory response in CD8 subset. Interestingly, impairment of the CD4+ AIM+ memory was associated to a more severe COVID-19 infection. Ibrutinib therapy had negative impact on IL-2 production by CD8+ cells, while the duration of the treatment positively affected the memory response. The majority of CLL patients don't respond well to vaccination, leaving clinicians in need of a reliable way to identify non-responders and assess the protection levels of those who do. Our findings suggest the AIM test as a promising method for screening and categorizing patients, potentially addressing this need.
引用
- Raineri D, Mazzucca CB, Moia R, et al. Impairment of the T cell memory response in chronic lymphocytic leukemia patients after SARS-CoV-2 vaccination. Vaccine. 2025. PMID: 39827600. doi:10.1016/j.vaccine.2025.126723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。